Signaling pathways for cardiac hypertrophy and failure

New England Journal of Medicine

Volumn 341, Issue 17, 1999, Pages 1276-1283

  Hunter, John J ^a   Chien, Kenneth R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE MUTATION; HEART DILATATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HISTOPATHOLOGY; HUMAN; MEDICAL GENETICS; MORPHOMETRICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; CARDIOMEGALY; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MUTATION; MYOCARDIAL CONTRACTION; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 0033592754     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910213411706     Document Type: Review

References (54)

1. Chien KR, Grace AA. Principles of cardiovascular molecular and cellular biology. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. Vol. 2. Philadelphia: W.B. Saunders, 1997:1626-49.
2. Chien KR. Stress pathways and heart failure. Cell 1999;98:555-8.
3. Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993;55:77-95.
4. Seidman CE, Seidman JG. Molecular genetics of inherited cardiomyopathies. In: Chien KR, ed. Molecular basis of cardiovascular disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 1999: 251-63.
5. Curran ME, Sanguinetti MC, Kearing MT. Molecular basis of inherited cardiac arrhythmias. In: Chien KR, ed. Molecular basis of cardiovascular disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 1999:302-12.
6. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 1991;5:3037-46.
7. Hunter JJ, Grace AA, Chien KR. Molecular and cellular biology of cardiac hypertrophy and failure. In: Chien KR, ed. Molecular basis of heart disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 1999:211-50.
8. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31.
9. Wang Y, Huang S, Sah W, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998;273:2161-8.
10. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998;273:5423-6.
11. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alphal-adrenergic receptor signaling in cardiomyocytes: dissociation of Ras and Rho pathways. J Biol Chem 1996;271:31185-90.
12. Chien KR. Genes and physiology: molecular physiology in genetically engineered animals. J Clin Invest 1996;97:901-9.
13. Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 1991;88:8277-81. [Erratum, Proc Natl Acad Sci U S A 1991;88:9907.]
14. Rockman HA, Ono S, Ross RS, et al. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci U S A 1994;91:2694-8.
15. Lin MC, Rockman HA, Chien KR. Heart and lung disease in engineered mice: technological miniaturization combined with the power of molecular genetics makes the mouse a model animal for understanding human cardiovascular and pulmonary disease. Nat Med 1995;1:749-51.
16. Christensen G, Wang Y, Chien KR. Physiological assessment of complex cardiac phenotypes in genetically engineered mice. Am J Physiol 1997; 272.-H2513-H2524.
17. Hunter JJ, Zhu H, Lee KJ, Kubalak S, Chien KR. Targeting gene expression to specific cardiovascular cell types in transgenic mice. Hypertension 1993;22:608-17.
18. Thorburn A, Thorburn J, Chen SY, et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 1993;268:2244-9. [Erratum, J Biol Chem 1993; 268:16082.]
19. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270: 23173-8.
20. Gottshall KR, Hunter JJ, Tanaka N, et al. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc Natl Acad Sci U S A 1997;94:4710-5.
21. Kai H, Muraishi A, Sugiu Y, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 1998;83:594-601.
22. Young SG, Lusis AJ, Hammer RE. Genetically modified animal models in cardiovascular research. In: Chien KR, ed. Molecular basis of cardiovascular disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 1999:37-85.
23. Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997;88:393-403.
24. Chen J, Kubalak SW, Chien KR. Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development 1998;125:1943-9.
25. Hirota H, Chen J, Betz UAK, et al. Loss of a gpl30 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999;97:189-98.
26. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrinc mechanism for myocardial cell hypertrophy. J Biol Chem 1990;265:20555-62.
27. Yamazaki T, Komuro I, Kudoh S, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996; 271:3221-8.
28. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the ATI receptor subtype. Circ Res 1993;73:413-23.
29. Idem. The heterotrimeric G q protein-coupled angiotensin II receptor activates p21 ras via the tyrosine kinase-Shc-Grb2-Sos pathway in cardiac myocytes. EMBO J 1996;15:775-87.
30. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: assembly of sarcomeric units in series VIA gpl30/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 1996;271:9535-45.
31. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway: divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 1997; 272:5783-91.
32. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytcs. Circulation 1993;87:1715-21.
33. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95: 619-27.
34. Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A 1994;91:10109-13.
35. LaMorte VJ, Thorbum J, Absher D, et al. Gq- and ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following alpha 1-adrenergic stimulation. J Biol Chem 1994;269:13490-6.
36. D'Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997;94:8121-6.
37. Adams JW, Sakata Y, Davis MG, et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A 1998;95:10140 5.
38. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998;280:574-7.
39. Graver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental overexpression of calmodulin induces proliferate and hypertrophic growth of cardiomyocytes in transgcnic mice. Endocrinology 1993;133: 376-88.
40. Molkenrin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
41. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A 1998;95:13893-8.
42. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-7.
43. Olson TM, Michels W, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-2.
44. Chen J, Chien KR. Complexity in simplicity: monogenic disorders and complex cardiomyopathies. J Clin Invest 1999;103:1483-5.
45. ++ cycling defect that drives the progression of dilated cardiomyopathy. Cell (in press).
46. Kadambi VJ, Ponniah S, Harrer JM, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996;97:533-9.
47. Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996;272:731-4.
48. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in betal-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999-96:7059-64.
49. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994;264:582-6.
50. Iwase M, Bishop SP, Ucchi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ Res 1996;78:517-24.
51. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing die beta-adrenergic receptor kinase or a beta ARK inhibitor Science 1995;268:1350-3.
52. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994;75:401-9.
53. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase I inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998;957000-5.
54. Xiao RP, Avdonin P, Zhou YY, et al. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 1999;84:43-52.